Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response

Fig. 2

Comparison of the change (delta) from baseline to follow-up visit of lung function, blood eosinophils, capillary oxygenation, quality of life and asthma control test between both groups (responder vs non-responder). Percentages are stated as % of predicted. a FEV1, forced expiratory volume in one second; b RV residual volume; c Eos eosinophils; d QoL quality of life, VAS visual analogue scale; e pO2 partial pressure of oxygen; f ACT asthma control test

Back to article page